Accéder au contenu
Merck

High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling.

Nature communications (2015-09-12)
Yuanbiao Zhao, Pilar Londono, Yingqiong Cao, Emily J Sharpe, Catherine Proenza, Rebecca O'Rourke, Kenneth L Jones, Mark Y Jeong, Lori A Walker, Peter M Buttrick, Timothy A McKinsey, Kunhua Song
RÉSUMÉ

Direct reprogramming of fibroblasts into cardiomyocytes by forced expression of cardiomyogenic factors, GMT (GATA4, Mef2C, Tbx5) or GHMT (GATA4, Hand2, Mef2C, Tbx5), has recently been demonstrated, suggesting a novel therapeutic strategy for cardiac repair. However, current approaches are inefficient. Here we demonstrate that pro-fibrotic signalling potently antagonizes cardiac reprogramming. Remarkably, inhibition of pro-fibrotic signalling using small molecules that target the transforming growth factor-β or Rho-associated kinase pathways converts embryonic fibroblasts into functional cardiomyocyte-like cells, with the efficiency up to 60%. Conversely, overactivation of these pro-fibrotic signalling networks attenuates cardiac reprogramming. Furthermore, inhibition of pro-fibrotic signalling dramatically enhances the kinetics of cardiac reprogramming, with spontaneously contracting cardiomyocytes emerging in less than 2 weeks, as opposed to 4 weeks with GHMT alone. These findings provide new insights into the molecular mechanisms underlying cardiac conversion of fibroblasts and would enhance efforts to generate cardiomyocytes for clinical applications.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Sérum de chèvre
Sigma-Aldrich
Sérum d'âne
Sigma-Aldrich
Anticorps monoclonal anti-α-actinine (sarcomérique) antibody produced in mouse, clone EA-53, ascites fluid
Sigma-Aldrich
Anti-Connexin-43 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Thiazovivin, ≥98% (HPLC)